Fortrea (FTRE) Stock Forecast & Price Target

$26.92

+0.70 (+2.67%)

(As of 07/26/2024 ET)

Fortrea - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 12 Analyst Ratings

Based on 12 Wall Street analysts who have issued ratings for Fortrea in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 1 has given a sell rating, 6 have given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for FTRE.

Consensus Price Target

$31.70
17.76% Upside

High Forecast	$44.00
Average Forecast	$31.70
Low Forecast	$26.00

According to the 12 analysts' twelve-month price targets for Fortrea, the average price target is $31.70. The highest price target for FTRE is $44.00, while the lowest price target for FTRE is $26.00. The average price target represents a forecasted upside of 17.76% from the current price of $26.92.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Hold	Moderate Buy	Hold	N/A
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	4 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	N/A
Hold	6 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)	N/A
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	N/A
Consensus Price Target	$31.70	$32.30	$37.29	N/A
Forecasted Upside	17.76% Upside	13.67% Upside	12.81% Upside	N/A

Get Fortrea Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FTRE and its competitors with MarketBeat's FREE daily newsletter.

Ad DTI

We’re in a code red crisis and 99% of Americans are clueless

Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES!

And how YOU can prepare for the next 2024 BOOM here!

FTRE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FTRE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Fortrea Stock vs. The Competition

Type	Fortrea	Medical Companies	S&P 500
Consensus Rating Score	2.42	2.72	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	17.76% Upside	2,864.75% Upside	9.14% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/24/2024	Barclays 2 of 5 stars	L. Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy ➝ Equal Weight	$30.00	+15.12%
7/18/2024	Bank of America 4 of 5 stars		Lower Target	Underperform ➝ Underperform	$27.00 ➝ $26.00	-3.60%
6/6/2024	The Goldman Sachs Group 2 of 5 stars		Initiated Coverage	Neutral	$28.00	+2.38%
5/29/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$27.00	+7.14%
5/28/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$27.00	+5.68%
5/23/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$36.00 ➝ $28.00	+9.33%
5/14/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/14/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$43.00 ➝ $31.00	+10.28%
5/14/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$45.00 ➝ $36.00	+28.07%
1/5/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Smock Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform
1/4/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$44.00	+32.13%
12/11/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$34.00 ➝ $40.00	+30.46%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:10 PM ET.

FTRE Forecast - Frequently Asked Questions

What is Fortrea's forecast for 2024?: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Fortrea is $31.70, with a high forecast of $44.00 and a low forecast of $26.00.
Should I buy or sell Fortrea stock right now?: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fortrea in the last year. There is currently 1 sell rating, 6 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" FTRE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FTRE, but not buy additional shares or sell existing shares.
Does Fortrea's stock price have much upside?: According to analysts, Fortrea's stock has a predicted upside of 14.47% based on their 12-month stock forecasts.
Has Fortrea been upgraded by Wall Street analysts recently?: Over the previous 90 days, Fortrea's stock had 2 upgrades by analysts.
What analysts cover Fortrea?: Fortrea has been rated by research analysts at Baird R W, Bank of America, Barclays, Deutsche Bank Aktiengesellschaft, Evercore ISI, Mizuho, Robert W. Baird, TD Cowen, and The Goldman Sachs Group in the past 90 days.
Do Wall Street analysts like Fortrea more than its competitors?: Analysts like Fortrea less than other "medical" companies. The consensus rating for Fortrea is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FTRE compares to other companies.